News & Media

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce positive results of the Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia (NCT03548584). The analysis concluded that there is a statistically significant difference (p=0.0026) in the mean change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score between brexpiprazole and placebo.

Otsuka Pharmaceutical Co., Ltd.  announces that it has decided to terminate its global license agreements with Akebia Therapeutics, Inc. for vadadustat (generic name), under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia). These licenses were signed in in December 2016 for the U.S. and April 2017 for Europe and other regions.

Otsuka America Pharmaceutical, Inc. hosted its 4^th annual Advancing Mental Health Policy Forum on Monday, May 9, 2022 at Hyatt Regency on Capitol Hill. The forum brought together federal and state policymakers as well as key advocacy partners and other experts from the mental health community who are passionate about transforming the way mental illness is treated. Grammy Award-winning singer-songwriter, actress and mental health advocate Michelle Williams, member of Destiny’s Child, served as keynote speaker and shared her personal experience living with depression.

Otsuka’s Economic and Health Impact in the United States highlights the contributions of Otsuka’s U.S. pharmaceutical subsidiaries — Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Collectively, the subsidiaries comprise nearly 2,000 employees at three corporate offices and other locations in the United States working in all aspects of bringing new medicines to market, from research and development to commercialization.